1 Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products ; web William E. Winter, MD University of Florida Departments of Pathology and Pediatrics
2 Learning objectives: At the conclusion of this presentation, the laboratorian will be able to: 1. List the forms of testosterone (T) that circulate. 2. Explain how total and free T are best measured. 3. Describe how free T falls with advancing age. 4. Recall the symptoms of late-onset hypogonadism. 5. Diagnose late-onset hypogonadism. 6. Anticipate the clinical demand for T testing. 7. Explain the risks of T replacement. 8. Plan appropriate monitoring for men treated w/ T. 9. Discuss the benefits and risks of T replacement tx.
3 To fulfill your responsibilites as a man, despite your insecurities and constant ability to place yourself in embarrasing and un-manly scenarios.
4 Testosterone results in 45 minutes!
5 In what forms does testosterone circulate in the body? Free 2% Biologically active Bound Albumin - Loosely (weakly) bound 54% 98% SHBG - Tightly bound* 44% Bioavailable T (BAT) * Precipitable w/ ammonium sulfate (T total T ASP = BAT) Effect of androgens on SHBG: Decr. (-- > incr. free T) ASP = ammonium sulfate precipitable testosterone; T distribution reference: Lepage R. Measurement of testosterone and its sub-fractions in Canada. Clin Biochem Feb;39(2):
6 How should testosterone be measured? Age group Adolescent males and adult men Children and women Method Immunoassay is satisfactory Mass spectroscopy (need lower limits of detection)
7 How can free testosterone be determined? Dialysis equilibrium Ultrafiltration < --- definitive method (labor intensive) < --- definitive method (labor intensive) Analog methods Free androgen index Calculated from total T & SHBG
8 How can free testosterone best be determined in routine clinical laboratories? Total T & SHBG (+/- albumin) --- > calculate free T Concentration Testosterone = FT(free) + Alb-bound-T + [SHBG]-bound-T Testosterone = [S] + [S A ] + [SP] Albumin [S A ] = constant = K A x C onc. Alb = 3.6x10 4 x 43g/l = 22.4 [S] =(molecular weight alb.) K A = = 3.6x104 for an average albumin conc. of 4.3 g/dl or [S A ] = [S] [S] + [S A ] = ( )[S] = [S] (1) SHBG [P] = free SHBG [SP] = steroid bound SHBG K = 10 9 M [S] +[P] «[SP] or [S] = [SP] (2) [P] [K] [P] + [SP] = [SHBG] or [P] = [SHBG] [SP] (3) Bioavailable [Bio T] = [S] + [S A ] Source: J Clin Endocrinol Metab 84: , 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum
9 When should testosterone be measured during the day? Age PM (1600) versus AM (0800)T y/o 20-25% lower 70 y/o 10% lower 2008 Guidelines: 7 AM 11 AM
10 What are the reference intervals for testosterone? Developmental Testosterone Stage (ng/dl) I <3 II <3-432 III IV V Adult male >19 y Source: Lab Corp
11 1143 Japanese men y/o The mean total T by age range decreases only to 80% of the young adult mean even during presenile and senile periods, when LOH occurs most frequently. International Journal of Urology (2009) 16, ; LOH = late-onset hypogonadism
12 1143 Japanese men y/o...free T level shows a linear decrease with aging and drops to 50% of the young adult mean. International Journal of Urology (2009) 16,
13 Critical issues in measuring testosterone & FT 1. Reference intervals among laboratories should NOT be interchanged (need lab-specific ref intervals). 2. There is uncertainty in all methods & measurements. 3. There is intra-individual variation. 4. For repeated measurements, use the same lab. 5. Measure in the AM (and the ~same time w/ every repeated measurement). 6. Low T dx (T & SHBG) requires confirmation: 2 samples 2 wks apart w/ CV i <20% (CV i =>20% - repeat again).
14 What are the symptoms of late-onset hypogonadism? (i) LOH is a syndrome characterized primarily by: (1)The easily recognized features of diminished sexual desire (libido) and erectile quality and frequency, particularly nocturnal erections, (2) Changes in mood with concomitant decreases in intellectual activity, cognitive functions, spatial orientation ability, fatigue, depressed mood and irritability, (3) Sleep disturbances, (4) Decrease in lean body mass with associated diminution in muscle volume and strength, Source: Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males ISA, ISSAM, and EAU recommendations. European Urology. 2005;48:1 4.
15 What are the symptoms of late-onset hypogonadism? (ii) (5) Increase in visceral fat, (6) Decrease in body hair and skin alterations, (7) Decreased bone mineral density resulting in osteopenia, osteoporosis and increased risk of bone fractures. Source: Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males ISA, ISSAM, and EAU recommendations. European Urology. 2005;48:1 4.
16 What is the definition of late-onset hypogonadism? Many definitions: LOH is defined as a total testosterone level <300 ng/dl combined with the presence of three sexual symptoms: Decreased frequency of morning erections Erectile dysfunction Decreased frequency of sexual thoughts Source: Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent) Oct;27(4):321-4.
18 Does male menopause (manopause, male climacteric, late-onset hypogonadism) actually occur? FACT: Total and free T decline w/ incr. age Symptoms of hypogonadism: ~ lack specificity & can be accounted for by other comorbidities: chronic illness, depression, etc. It is likely that LOH does really occur (as does normal aging) Diagnosis of LOH: Symptoms (+) low total T if total T: WNL --- > measure free T
19 How common is late-onset hypogonadism? The actual prevalence of hypogonadism has been estimated to be 39% in men aged 45 years or older presenting to primary care offices in the United States. Source: Rivas AM, Mulkey Z, Lado-Abeal J, Yarbrough S. Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent) Oct;27(4): Massachusetts Male Aging Study: Total T: <400 ng/dl (+) 3 signs/symptoms of low T: Prevalence of 6% to 12%. Source: O Donnell AB, Araujo AB, McKinlay JB. The health of normally aging men: The Massachusetts Male Aging Study ( ). Exp Gerontol 2004;39(7):
20 When should testosterone replacement be considered in symptomatic men? Total T: <230 mg/dl Tx ed men usually benefit >350 mg/dl Tx not required mg/dl Measure free T or BAT (especially for obese men) International Society of Andrology (ISA) International Society for the Study of Aging Male (ISSAM) European Association of Urology (EAU) European Academy of Andrology (EAA) American Society of Andrology (ASA) Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol Nov;159(5):
21 What are the economics of pharmacologic treatment of sexual dysfunction or androgen deficiency?
22 Worldwide Viagra revenue 2013: $1.881 billion
23 Annual testosterone revenue in U.S. 2013: $2.4 billion Projected*: 2018: $3.8 billion * Prior to March 3, 2015 FDA warning
24 What is the impact on laboratory services for requests for testosterone measurements? Study group: 321, y/o men; 2009 to Result: 3.2% had a testosterone measurement for any reason! P Hz of testing: 2.5% 3.6% < % incr. in 3 yrs Malik RD, Lapin B, Wang CE, Lakeman JC, Helfand BT. Are we testing appropriately for low testosterone?: characterization of tested men and compliance with current guidelines. J Sex Med Jan;12(1): in 5 men treated w/ T: normal T - Men treated by endocrinologists & urologists: more Hz ly have a low T Baillargeon J, Urban RJ, Kuo YF, Holmes HM, Raji MA, Morgentaler A, Howrey BT, Lin YL, Ottenbacher KJ. Screening and monitoring in men prescribed testosterone therapy in the u.s., Public Health Rep Mar- Apr;130(2):
25 What are the risks of testosterone therapy? Adverse androgen effects: - Increased aggression/behavior changes - Polycythemia - Prostate enlargement - Venous thrombo-embolism - Dyslipidemia - Hypertension - AMI, stroke
26 March 3, 2015 FDA warning! Hazard ratios for MI, stroke and/or death:
27 How should testosterone-treated men be monitored? Lab Testosterone Hb/Hct Lipids AST PSA Semen analysis Comment Monitoring Risk of polycythemia Risk of dyslipidemia Risk of hepatotoxicity Concern regarding risk of prostate cancer If infertility is present: reduced sperm Non-Lab BP DRE DexaScan Salt retention, incr. BP Concern regarding risk of prostate cancer BMD should incr. w/ T tx Best Pract Res Clin Endocrinol Metab Jan;29(1): doi: /j.beem Epub 2014 Oct 2. Current topics in testosterone replacement of hypogonadal men. Nieschlag E. Author information Abstract All forms of hypogonadism - primary, secondary and late-onset - require testosterone substitution. The indication is given when the patient presents with symptoms of androgen deficiency and the serum testosterone levels are below normal. Several testosterone preparations and modes of application are available of which those producing physiologic serum levels should be preferred e.g. preferentially transdermal gels and long-acting intramuscular testosterone undecanoate. Testosterone substitution must be monitored at regular intervals, best at 3, 6 and 12 months after initiation and then annually. Parameters for surveillance include well-being, libido and sexual activity, measurement of serum testosterone levels, haemoglobin and haematocrit, PSA and digital rectal examination, and, biannually, bone mineral density. Testosterone has positive effects on comorbidities such as obesity, metabolic syndrome, diabetes type II, cardiovascular diseases and osteoporosis.
28 Does testosterone therapy benefit older men? (i) Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab Apr;87(4):
29 Does testosterone therapy benefit older men? (ii) Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab Aug;27(4): Late-onset hypogonadism (LOH) is a relatively common conditions affecting the aging male. The aim of this review is to summarize the available evidence regarding LOH and its interaction with general health. LOH is often comorbid to obesity and several chronic diseases. For this reason lifestyle modifications should be strongly encouraged in LOH subjects with obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) and good treatment balance of chronic diseases. Medical therapy of LOH should be individualized depending on the etiology of the disease and the patient's expectations. Available evidence seems to suggest that testosterone replacement therapy is able to improve central obesity (subjects with MetS) and glycometabolic control (patients with MetS and T2DM), as well as to increase lean body mass (HIV, chronic obstructive pulmonary disease), along with insulin resistance (MetS) and peripheral oxygenation (chronic kidney diseases). However,... it should be recognized that the number of studies on benefits of T supplementation is too limited to draw final conclusions. Longer and larger studies are needed to better clarify the role of TRT in such chronic conditions.
30 Caveat emptor (Let the buyer beware... ) Corona G, Rastrelli G, Maseroli E, Forti G, Maggi M. Sexual function of the ageing male. Best Pract Res Clin Endocrinol Metab Aug;27(4): With the progressive increase in the proportion of older people, there is an increasing interest in characterizing the modifications of sexual health and the effect of its perturbations as a function of the aging process. The aim of this review is to summarize the available evidence regarding the age-dependent modifications of male sexual function and their interaction with general health and age-dependent modification of endocrine function. Elderly patients are often affected by multiple organic diseases which can interfere with sexual function. Despite this evidence, several studies have indicated that, with advancing age, normal erections are not an absolute prerequisite to remain sexually active. Good physical health, the availability of a partner, and a regular and stable pattern of sexual activity earlier in life predict the maintenance of sexual activity in old age. Conversely, there are no convincing data that hormonal changes, associated with aging, have a primary role in underlying changes in sexual function in healthy aging men. Nonetheless, sexual dysfunctions especially in elderly people are poor investigated. Asking about sexual health remains difficult or embarrassing for many primary care physicians. In addition, many patients find it difficult to raise sexual issues with their doctor. This situation often results in sexual issues not being adequately addressed thus resulting in depression, social withdrawal and delayed diagnosis of underlying medical conditions often resulting in forthcoming cardiovascular events. Education and permission from a health care professional may help to alter such misconceptions. Information from physicians regarding normal age-related changes in sexuality and encouragement, together with advice on how to continue meaningful sexual relations, may play a key role in altering such negative attitudes.
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
DEFINITION A hormone that is a hydroxyl steroid ketone (C19H28O2) produced especially by the testes or made synthetically and that is responsible for inducing and maintaining male secondary sex characteristics.
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria
The Male Andropause By: Dr. Sangeeta Pati MD, FACOG Although, the male andropause has not been widely recognized, increased medical research has turned attention to the gradual hormone decline in males
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
The Aging Male, December 2007; 10(4): 211 216 WORKSHOP REPORT Functional testosterone: Biochemical assessment of hypogonadism in men Report from a multidisciplinary workshop hosted by the Ontario Society
ANDROGEN DEFICIENCY/MALE HYPOGONADISM 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone (androgen deficiency)
MALE HYPOGONADISM: CHOOSING THE APPROPRIATE THERAPY Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Aromatase inhibitors & clomiphene citrate are
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
Medical Information to Support the Decisions of TUE Committees 1. Medical Condition Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of
Testosterone: Current Opinion and Controversy Ravi Kacker, MD Metrowest Urology (508) 655 4422 Medical Office Building at Leonard Morse Hospital Disclosures MHB Labs President and CEO of Drug Development
Consent for Testosterone Therapy in Men You have been diagnosed with or have an increased risk of having a hormone deficiency and your provider has recommended treatment with bio-identical hormone replacement
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.619 Sexual Dysfunction/Male Infertility Serum Total Testosterone Level and Identification of Late-Onset Hypogonadism: A Community-Based Study Sungmin
CLINICAL PRACTICE GUIDELINE Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline Shalender Bhasin, 1 Juan P. Brito, 2 Glenn R. Cunningham, 3 Frances J. Hayes,
European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire
96 Harley Street (London) and Manchester All Enquiries - +44 (0)20 7486 2277 www.centreformenshealth.co.uk/ This leaflet provides information about: The Centre for Men s Health The conditions we treat:
J. Andrew Hoover, MD; Jeffrey T. Kirchner, DO, FAAFP Department of Family and Community Medicine, Lancaster General Hospital, Pa firstname.lastname@example.org The authors reported no potential conflict of interest
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely
THE RECEPTOR Message from the Chair Hubert Vesper, PhD, Centers for Disease Control and Prevention Greetings! The 2015 AACC Annual Meeting begins very soon and I would like to take this time to encourage
An Update on Men s Health and Sexual Function Lawrence Jenkins, MD, MBA Assistant Professor Clinical Department of Urology The Ohio State University Wexner Medical Center Outline Testosterone Deficiency
Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
APPROACH TO HYPOGONADAL MEN Michael S. Irwig, M.D. Director, Center for Andrology Division of Endocrinology & Metabolism Disclosures Pharma-Free Presentation My andrology clinic Controversy with Testosterone
Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga
Male hypogonadism & testosterone replacement therapy Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported
Preparing for the road ahead LEARN MORE ABOUT these 5 risks to A MAN S health 3 4 5 2 6 1 7 0 8 9 WHY DOES IT SEEM LIKE SOME MEN TAKE BETTER CARE OF THEIR CARS THAN THEIR OWN HEALTH? When the check engine
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
136 Review Asian Journal of Andrology (2010) 12: 136 151 2010 AJA, SIMM & SJTU All rights reserved 1008-682X/09 $ 32.00 www.nature.com/aja Androgens and male aging: current evidence of safety and efficacy
Testosterone Supplementation, Prostate Cancer Screening and Vitamins Peter J. Burrows MD FACS Clinical Assistant Professor of Urology University of Arizona, College of Medicine Adjunct Assistant Professor
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
1 The Low T Book A Man s 30 Day Guide To Improve Your Strength Energy Libido & Fitness Chapter 1 The State of Male Health What You Don t Know May Kill You Every Man s Problem! In men the symptoms of testosterone
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
Guidelines for the Clinical Care of Persons with Gender Dysphoria Friday, May 27, 2016 2:15 5:00 PM 25 th Annual Scientific and Clinical Congress American Association of Clinical Endocrinologist Orlando,
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
Sexual Medicine Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Jason M. Scovell, Ranjith Ramasamy, Nathan Wilken, Jason R. Kovac and Larry I. Lipshultz
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
SPECIAL FEATURE Clinical Practice Guideline Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline Shalender Bhasin, Glenn R. Cunningham, Frances
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
SPECIAL ARTICLE Adult-Onset Hypogonadism Mohit Khera, MD, MBA, MPH; Gregory A. Broderick, MD; Culley C. Carson III, MD; Adrian S. Dobs, MD, MHS; Martha M. Faraday, PhD; Irwin Goldstein, MD; Lawrence S.
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY email@example.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history